Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s.
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
BOSTON, Mass., Feb. 27, 2024 Pyxis Oncology, Inc. , a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it has.
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.